Irini Chatziralli1, George Theodossiadis2, Marilita M Moschos3, Panagiotis Mitropoulos4, Panagiotis Theodossiadis5. 1. 2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 28, Papanastasiou street, Agios Dimitrios, 17342, Athens, Greece. eirchat@yahoo.gr. 2. 2nd Department of Ophthalmology, Henry Dunant Hospital, Athens, Greece. 3. 1st Department of Ophthalmology, University of Athens, Athens, Greece. 4. 2nd Department of Ophthalmology, Ophthalmiatrion Athinon, Athens, Greece. 5. 2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 28, Papanastasiou street, Agios Dimitrios, 17342, Athens, Greece.
Abstract
PURPOSE: The objective of this study was to compare the anatomical and functional outcomes of ranibizumab versus aflibercept for the treatment of macular edema due to central retinal vein occlusion (CRVO) in routine clinical practice. METHODS: Participants in this observational study included 62 treatment-naïve patients with CRVO who received intravitreal injections of either ranibizumab or aflibercept. The demographic data, best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) characteristics were evaluated at baseline and at months 1, 2, 3, 6, 12 and 18 post-treatment. RESULTS: At month 18, the mean BCVA of ranibizumab-treated eyes increased 7.9 letters, compared to 7.4 letters for eyes receiving aflibercept, with a similar number of injections. There was no statistically significant difference between the two groups in letters or in central subfield thickness at month 18. At the end of the follow-up, 50% of patients in the ranibizumab group and 42.9% in the aflibercept group showed complete resolution of macular edema. CONCLUSIONS: Ranibizumab and aflibercept demonstrated similar anatomical and functional outcomes over 18-month follow-up in patients with macular edema due to CRVO, with a similar number of injections.
PURPOSE: The objective of this study was to compare the anatomical and functional outcomes of ranibizumab versus aflibercept for the treatment of macular edema due to central retinal vein occlusion (CRVO) in routine clinical practice. METHODS:Participants in this observational study included 62 treatment-naïve patients with CRVO who received intravitreal injections of either ranibizumab or aflibercept. The demographic data, best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) characteristics were evaluated at baseline and at months 1, 2, 3, 6, 12 and 18 post-treatment. RESULTS: At month 18, the mean BCVA of ranibizumab-treated eyes increased 7.9 letters, compared to 7.4 letters for eyes receiving aflibercept, with a similar number of injections. There was no statistically significant difference between the two groups in letters or in central subfield thickness at month 18. At the end of the follow-up, 50% of patients in the ranibizumab group and 42.9% in the aflibercept group showed complete resolution of macular edema. CONCLUSIONS:Ranibizumab and aflibercept demonstrated similar anatomical and functional outcomes over 18-month follow-up in patients with macular edema due to CRVO, with a similar number of injections.
Authors: Maximilian Pfau; Heidi Fassnacht-Riederle; Matthias D Becker; Nicole Graf; Stephan Michels Journal: Ophthalmic Res Date: 2015-09-29 Impact factor: 2.892
Authors: Raafay Sophie; Gulnar Hafiz; Adrienne W Scott; Ingrid Zimmer-Galler; Quan Dong Nguyen; Howard Ying; Diana V Do; Sharon Solomon; Akrit Sodhi; Peter Gehlbach; Elia Duh; David Baranano; Peter A Campochiaro Journal: Am J Ophthalmol Date: 2013-10 Impact factor: 5.258
Authors: Peter A Campochiaro; David M Brown; Carl C Awh; S Young Lee; Sarah Gray; Namrata Saroj; Wendy Yee Murahashi; Roman G Rubio Journal: Ophthalmology Date: 2011-06-29 Impact factor: 12.079
Authors: Michael Larsen; Sebastian M Waldstein; Francesco Boscia; Heinrich Gerding; Jordi Monés; Ramin Tadayoni; Siegfried Priglinger; Andreas Wenzel; Elizabeth Barnes; Stefan Pilz; William Stubbings; Ian Pearce Journal: Ophthalmology Date: 2016-02-17 Impact factor: 12.079
Authors: Cláudia Farinha; João Pedro Marques; Elisabete Almeida; Alda Baltar; Ana Rita Santos; Pedro Melo; Miguel Costa; João Figueira; Maria Luz Cachulo; Isabel Pires; Rufino Silva Journal: Ophthalmic Res Date: 2015-11-06 Impact factor: 2.892
Authors: L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park Journal: N Engl J Med Date: 1994-12-01 Impact factor: 91.245
Authors: Philip Hykin; A Toby Prevost; Sobha Sivaprasad; Joana C Vasconcelos; Caroline Murphy; Joanna Kelly; Jayashree Ramu; Abualbishr Alshreef; Laura Flight; Rebekah Pennington; Barry Hounsome; Ellen Lever; Andrew Metry; Edith Poku; Yit Yang; Simon P Harding; Andrew Lotery; Usha Chakravarthy; John Brazier Journal: Health Technol Assess Date: 2021-06 Impact factor: 4.014
Authors: Sanjeeb Bhandari; Vuong Nguyen; Adrian Hunt; Pierre-Henry Gabrielle; Francesco Viola; Hemal Mehta; Les Manning; David Squirrell; Jennifer Arnold; Ian L McAllister; Daniel Barthelmes; Mark Gillies Journal: Eye (Lond) Date: 2022-05-04 Impact factor: 4.456
Authors: Mateusz Niedzwiecki; Adrian Hunt; Vuong Nguyen; Hemal Mehta; Catherine Creuzot-Garcher; Pierre-Henry Gabrielle; Martin Guillemin; Samantha Fraser-Bell; Jennifer Arnold; Ian L McAllister; Mark Gillies; Daniel Barthelmes Journal: Acta Ophthalmol Date: 2021-09-13 Impact factor: 3.988